FindTrial
Sign In

Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Based Chemotherapy in Patients with Pancreatic Cancer: A Cohort Study

Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Based Chemotherapy in Patients with Pancreatic Cancer: A Cohort Study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100051520
Enrollment
Unknown
Registered
2021-09-25
Start date
2021-10-01
Completion date
Unknown
Last updated
2022-06-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pancreatic cancer

Interventions

Case series:No

Sponsors

West China Hospital, Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. For patients with pancreatic cancer confirmed by pathology, the diagnosis should be combined with pathology and imaging (CT or MRI) for comprehensive judgment; 2. Age above 18 years old, gender is not limited.

Exclusion criteria

Exclusion criteria: 1. Clinical data (including medical records, imaging examinations, etc.) cannot judge the curative effect; 2. Those who have not perfected genetic testing and whose pathological samples cannot be used to complete genetic testing; 3. Those who are unwilling to provide or cannot follow up survival data such as PFS, OS and other data; 4. Those who cannot obtain the informed consent of the patient or his family.

Design outcomes

Primary

MeasureTime frame
objective response rate;Progression-free survival;—

Secondary

MeasureTime frame
overall survival;—

Countries

China

Contacts

Public ContactCao Dan

West China Hospital, Sichuan University

caodan@scu.edu.cn+86 18980605963

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026